Litigation

Incyte Genomics, Inc. v. Gene Logic, Inc.

settled

3:00-cv-04627

Patents at issue (3)

5891636
5716785
6023659

Defendants (1)

Summary

Incyte Genomics, Inc., as exclusive licensee of Stanford's patents, sued Gene Logic, Inc. for infringement in the Northern District of California. The case asserted U.S. 5,716,785, U.S. 5,891,636, and U.S. 6,023,659. It settled in January 2001, the lawsuits were dismissed, and Gene Logic received a non-exclusive license.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

I'll research this case to verify the details before drafting the overview.

Let me verify the patents, parties, and docket specifics.

Case overview and background

Parties and posture. Incyte Genomics, Inc. v. Gene Logic, Inc., No. 3:00-cv-04627 (N.D. Cal.), was a competitor-versus-competitor patent fight between two genomics-information companies during the height of the first "genomics gold rush." Incyte (Palo Alto, CA) built and sold genomic databases (LifeSeq/PathoSeq), bioinformatics software, and microarray-based gene-expression services; Stanford's NPE litigation database classifies it as a "product company," not a patent monetizer (https://npe.law.stanford.edu/case/[141656](/patent/141656)). Gene Logic (Gaithersburg, MD) was Incyte's direct competitor in gene-expression databases and bioinformatics services, and later reinvented itself as a preclinical contract research organization. The suit was filed August 17, 2000, per an attorney-of-record listing for the case number (the "3:" prefix places it in the court's San Francisco Division); it was one of two Incyte suits against Gene Logic — Incyte's 10-Q confirms suits against Gene Logic filed "in December 1999 and August 2000," with the December 1999 action asserting the same RNA-amplification patents. Gene Logic counterclaimed, alleging unfair competition under California statutory and common law, and sought damages, costs, and fees (Incyte 10-Q, Q3 2000, https://www.companiesmarketcap.com/nzd/incyte/sec-reports-10q/0000879169-00-000067/). The case settled in January 2001: the lawsuits were dismissed and Gene Logic received a non-exclusive, fully paid-up license (BioCentury; BIOTECH Patent News, https://www.thefreelibrary.com/Incyte+licenses+comprehensive+microarray+patent+portfolio+to+Chiron.-a071900983).

Accused technology and patents. The accused products were Gene Logic's gene-expression database offerings and its use of non-PCR linear RNA amplification to generate expression data — i.e., the platform Incyte claimed was "fundamental to our genomic databases." Incyte's general counsel, Lee Bendekgey, stated Incyte "recently learned that Gene Logic is using this intellectual property in its gene expression databases" (https://www.bioprocessonline.com/doc/incyte-genomics-files-two-patent-infringement-0001). The three asserted patents were:

  • U.S. 5,716,785 — Eberwine/Van Gelder/Von Zastrow/Barchas antisense-RNA (aRNA) linear amplification using an oligo-dT primer carrying a T7 RNA polymerase promoter (the "Eberwine" method). Together with the '636, it covers non-PCR RNA amplification that lets researchers scale up RNA from cellular mRNA for microarray expression analysis.
  • U.S. 5,891,636 — companion continuation in the same Van Gelder/Eberwine linear RNA-amplification family; later patents consistently cite U.S. 5,545,522, 5,716,785 and 5,891,636 together as the core antisense-RNA amplification disclosure.
  • U.S. 6,023,659 — "Database system employing protein function hierarchies for viewing biomolecular sequence data" (Seilhamer et al., assigned to Incyte Pharmaceuticals, issued Feb. 8, 2000). Claims a computer system with a biomolecular-sequence database grouped into hierarchies of protein function categories, plus a user interface for viewing sequences by biological/molecular function — an early bioinformatics/software claim (https://patentimages.storage.googleapis.com/58/da/70/18bc339fc5f7d0/[US6023659](/patent/US6023659).pdf; https://insight.rpxcorp.com/patent/[US6023659A](/patent/US6023659A)).

One correction to the existing summary: the record indicates Incyte's exclusive license to the '785 and '636 came from Layton Bioscience, Inc. (with the inventors at the University of Pennsylvania), not Stanford — Incyte's own public statements and contemporaneous coverage say so repeatedly (BIOTECH Patent News; https://www.thefreelibrary.com/[Merck](/litigations/by-plaintiff/Merck)+licenses+gene+expression+data+microarray+technology+from+Incyte.-a074990923). Stanford is the assignee of Incyte's separate microarray-fabrication portfolio (U.S. 5,807,522 / 6,110,426, Shalon & Brown), which Incyte also licensed to Gene Logic as part of the January 2001 settlement.

Why the case is notable. Three things. First, it is an early example of a practicing company using platform IP offensively across an entire industry: Incyte asserted the same RNA-amplification patents against Affymetrix (August 2000) and Gene Logic, and licensed them non-exclusively to Merck, Chiron, and Linden Bioscience — a "license-or-litigate" campaign, but run by an operating genomics company rather than an NPE/PAE. Second, it is a rare pre-Alice assertion of a bioinformatics database/software patent (the '659), making it an early test of whether claims to sequence databases organized by protein-function hierarchies were patentable subject matter and enforceable against a competitor's database product. Third, the market context: the 2000–2001 genomics information industry was consolidating and patent portfolios on ESTs, amplification, and microarrays were the principal competitive weapons; the litigation was costly (Incyte disclosed roughly $5.6 million in legal expense in the first nine months of 2000 across the Affymetrix and Gene Logic matters) and the settlement converted a competitor into a licensee without any adjudicated validity or infringement ruling. There is no IPR linkage — the PTAB did not exist until 2012, and these patents (filed in the mid-1990s) were resolved well before inter partes review existed.

Sourcing caveats. I was unable to verify the assigned district judge, the exact docket entries, or counsel rosters from a primary docket in this pass; PACER/RECAP content for the case is not indexed in the sources I could reach. The reported filing date (8/17/2000) and counsel reference (Peter G. Mack, Foley & Lardner) come from a third-party attorney-listing database (https://ai-lab.exparte.com/attorney/[6075524](/patent/6075524)/peter-g-mack) and should be treated as unconfirmed. The license terms are redacted in the publicly filed settlement/license documents, but the agreement's structure — non-exclusive grants under the "Incyte Patents" and "Layton/Xxxxxx Patents," a stipulation of dismissal within three business days of payment, and retention of Incyte's right to sue for breach or third-party infringement — is visible in the publicly posted contract text (https://www.lawinsider.com/contracts/ksEy56ja0Xa). Financial settlement terms were expressly not disclosed.

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

I'll research this case using multiple searches to build a well-sourced chronology.

Let me dig deeper into the docket and the earlier Gene Logic suit.

I hit my research-call limit before I could pull PACER/CourtListener docket images, so I'll flag explicitly below where I'm relying on SEC filings, press coverage, and the settlement contract rather than docket-entry-level records. Here is the chronology.

Preliminary correction to the case framing

The existing summary describes Incyte as "exclusive licensee of Stanford's patents." That is only partly right and worth refining, because it affects how you read the asserted patents:

  • U.S. 5,716,785 and U.S. 5,891,636 — the Eberwine/Van Gelder/Von Zastrow/Barchas non-PCR (linear) RNA-amplification patents. Incyte took them by exclusive license from Layton Bioscience, Inc., not Stanford (BioTech Patent News, via TheFreeLibrary).
  • U.S. 6,023,659 — Incyte's own patent (invented by Incyte scientists), claiming a biomolecular-sequence database organized by protein-function hierarchies (BioProcess Online, 2000-08-22).
  • The Stanford patent in this family is U.S. 5,807,522 (Shalon/Brown microarray fabrication), which was not asserted but was swept into the settlement license.

Chronology of key developments

1. First Gene Logic action — filed December 1999

  • 1999-12 — Incyte (then Incyte Pharmaceuticals) filed its first infringement suit against Gene Logic in N.D. Cal., asserting U.S. 4,981,783 (disease-gene identification by hybridization/microarray assays) plus the two RNA-amplification patents, '785 and '636 (BioCentury; corroborated by BioCentury, 2000-08-18).
  • This "First Action" matters strategically: the eventual settlement agreement's claim charts and issue-preclusion clauses are keyed to it (see §6 below).

2. Complaint in the case at bar — 2000-08-17

  • 2000-08-17 — Incyte Genomics, Inc. v. Gene Logic, Inc., No. 3:00-cv-04627 (N.D. Cal.) filed, asserting U.S. 6,023,659 — the database-structure patent (Stanford NPE database, case 141656; filing date 08/17/00 also recorded in an attorney–case association for Peter G. Mack, Foley & Lardner — caveat: that third-party database does not state which party Mack represented, so treat counsel attribution as unverified).
  • Filed the same day as Incyte's suit against Affymetrix, part of a coordinated two-front enforcement campaign announced 2000-08-18/22.
  • Incyte's GC Lee Bendekgey framed it as protecting "intellectual property [that] is fundamental to our genomic databases," after learning "Gene Logic is using this intellectual property in its gene expression databases" (BioProcess Online).

3. Answer and counterclaims — Fall 2000

  • By ~2000-09/11 — Gene Logic answered and counterclaimed, alleging unfair competition under California statutory and common law, and seeking damages, costs, and attorney's fees. This is confirmed in Incyte's Form 10-Q for the quarter ended 2000-09-30: "Gene Logic has filed counterclaims alleging, among other things, that we committed acts of unfair competition under California statutory and common law. Gene Logic seeks, among other things, damages, costs and attorneys' fees" (Incyte 10-Q).
  • No IPR/stay motion practice is possible here — the AIA post-grant regime did not exist in 2000 (see §7).

4. Pre-trial motion practice, Markman, discovery, trial

  • None reached. I found no motion to dismiss, motion to transfer, preliminary-injunction ruling, Markman/claim-construction order, summary-judgment ruling, discovery order, trial, verdict, or JMOL/fee motion in this case. The litigation was resolved roughly five months after the second complaint and well before any substantive pretrial motion or claim-construction hearing.
  • Discovery relevance / strategic significance: The only discovery-flavored artifact I could verify is contractual. The claim charts from the First Action (the '785/'636 case) are expressly incorporated into the settlement's issue-preclusion provisions — meaning the infringement contentions served in discovery became the benchmark for what was "accused" and therefore what is now barred (Gene Logic–Incyte license, §4.5, Law Insider). That is the durable discovery consequence of this case.
  • Note the contrast with the parallel Incyte–Affymetrix litigation, which did produce a Markman order (2001-01-22, amended 2001-06-12), partial summary judgment (2001-05-02), and an indefiniteness ruling (2001-05-08) — see Affymetrix's 10-Q (CapEdge). Those rulings are Affymetrix docket activity, not Gene Logic.

5. Settlement and dismissal — January 2001

  • 2001-01 — The parties announced settlement of both Gene Logic actions. Under the deal, "the lawsuits will be dismissed and Gene Logic will have a non-exclusive license to practice the technology described in these patents." Financial terms were not disclosed (BioTech Patent News, 2001-01-01; BioCentury).
  • The license covered '785, '636, and '659, and separately U.S. 5,807,522 (Stanford microarray-fabrication patent) (BioCentury). The summary's statement that the settlement produced a "non-exclusive license" is confirmed.

6. Terms of the settlement/consent-dismissal structure (verified from the contract)

The executed agreement (publicly posted at Law Insider) shows the disposition was structured, not a bare voluntary dismissal:

  • §3.1 (Dismissal of the Actions): counsel were to file a Stipulation and [Proposed] Order of Dismissal within three business days of the settlement payment, expressly preserving Incyte's right to sue Gene Logic in N.D. Cal. for breach (infringement or contract) and vice versa.
  • §4.5 (Issue preclusion — infringement of the Eberwine/"Xxxxxx" patents by accused protocols): Gene Logic agreed it will not assert that its then-current and past RNA-amplification protocols infringe the '785/'636 family — with express issue-preclusive effect.
  • §4.6 (Issue preclusion — validity/enforceability): comparable preclusion as to the validity and enforceability of the Eberwine patents, subject to a carve-out (the clause "shall not apply if the [patents are] not appealable or from which no appeal is taken").
  • §2.1–2.4: non-exclusive, fully paid-up, non-transferable, worldwide licenses, non-sublicensable, with no extension of rights to Gene Logic's suppliers and a preservation of Incyte's right to sue third parties.
  • Incyte separately represented that the licensed patents were, to its knowledge, not invalid or unenforceable (Law Insider, warranties clause).

7. Parallel PTAB / IPR / PGR proceedings

  • None, and none possible as to the timing. These patents issued 1998–2000; the AIA inter partes review regime (35 U.S.C. §§ 311 et seq.) and PGR did not take effect until 2012-09-16, over a decade after this case settled. No IPR/PGR on '785, '636, or '659 in this matter exists in any record I can find, and the asserted patents have since expired (20-year terms measured from mid-1990s filings).
  • The relevant "parallel administrative proceeding" here is an interference, not an IPR — and it was in the Affymetrix track, not Gene Logic. In April 1999 the BPAI declared interferences between a Stanford application exclusively licensed to Incyte and Affymetrix's '305 and '992 patents; on 1999-09-10 the Board ruled Incyte failed its prima facie case; Incyte sought de novo district-court review on 1999-11-08. This proceeding was expressly excluded from the 2001-12-21 Incyte–Affymetrix settlement (Affymetrix 10-Q; Incyte 8-K, 2001-12-21). I could not confirm the ultimate outcome of that de novo review from the sources retrieved — treat it as unresolved here.

Bottom line / present posture

This was a short, license-negotiation-through-litigation case, not a merits case. Incyte filed two waves against Gene Logic (Dec. 1999 on '785/'636 (+'783); 2000-08-17 on '659), Gene Logic counterclaimed for California unfair competition, and the parties settled in January 2001, dismissing both actions and giving Gene Logic a non-exclusive license to '659, '785, '636, and '522, with issue-preclusion machinery tied to the first action's claim charts. The case is terminated/settled, and there is no PTAB parallel proceeding (the AIA review regime postdates it) and no intervening motion, Markman, trial, or appeal in this docket.

The case is strategically notable within Incyte's broader 2000–2001 campaign: the same '785/'636 RNA-amplification patents were asserted against Affymetrix (filed 2000-08-17, settled 2001-12-21 with cross-licenses) and later against Invitrogen (from 2001-10/11), and the '659 database patent was one of the first attempts to enforce bioinformatics database-structure claims — a theory that died with the settlement and was never judicially tested.

Limitations on sourcing: Docket-entry-level detail (ECF numbers, exact answer/counterclaim filing dates, the calendar date of the dismissal order) could not be retrieved — my PACER/CourtListener searches did not return the docket itself. The dates above are from SEC filings, contemporaneous trade press, the Stanford NPE litigation database, and the publicly posted settlement agreement. I did not locate any court opinion, Markman order, summary-judgment decision, or verdict in this case, and I found none indicating the case was ever decided on the merits.

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

I'll research the counsel of record for Incyte Genomics in this case.

Bottom line up front

I was unable to confirm the plaintiff's counsel of record from an authoritative docket source within this research pass. N.D. Cal. docket sheets from 2000 are not freely indexed (no RECAP/CourtListener docket text surfaced, and the PACER docket was not retrievable), and the searches I ran did not surface a firm press release, opinion, or Law360/Reuters item naming Incyte's litigation team in this case. Rather than guess, here is what is actually verifiable, flagged with its confidence level.

Attorneys surfaced by name

1. Peter G. Mack — Foley & Lardner LLP (apparent outside counsel; side not confirmed)

  • Source: a third-party attorney-appearance database (ai-lab.exparte.com) lists "Peter G. Mack, Foley & Lardner LLP" linked to docket number 3:00-CV-04627, N.D. Cal., Incyte Genomics Inc v. Gene Logic Inc, 08/17/00 — i.e., the filing date matches this case.
  • Caveat: that aggregator does not identify which party he appeared for, and its underlying data source is unclear. Foley & Lardner has a well-known patent litigation practice (Mack is a longtime patent litigator, Washington, D.C. office). I could not corroborate this appearance against PACER, a court order, or firm materials, so do not treat it as a confirmed plaintiff's-counsel entry. It is equally possible the entry derives from a related PTAB/reexamination or interference matter rather than the district court docket.

2. Lee Bendekgey — General Counsel, Incyte Genomics (in-house; not counsel of record)

  • Quoted in the August 2000 announcement of the Gene Logic suit (spelled "Lee Bendekgy" in the contemporaneous trade report): "As the pioneer of the genomic information business, Incyte has invented many enabling technologies… we feel it necessary to protect this intellectual property." (Bioprocess Online, Aug. 22, 2000 — https://www.bioprocessonline.com/doc/incyte-genomics-files-two-patent-infringement-0001)
  • Role: corporate in-house spokesperson/GC. Not an appearance in the docket.

3. Matthew Kaser — Incyte Genomics patent agent (in-house prosecution; not litigation counsel)

  • Listed work history: Patent Agent, Incyte Genomics, June 1998 – Aug. 2001 (drafting/prosecuting genomics applications). He is on the prosecution side and is not counsel of record in the infringement action.

What I could not establish

  • No confirmed lead counsel or local counsel name for Incyte in 3:00-cv-04627.
  • No named firm for Incyte's patent litigation team in either this case or the companion Incyte Genomics v. Affymetrix N.D. Cal. suit filed the same week.
  • No sealed-filing indication one way or the other (the case settled in January 2001 per the case summary, so the record may be thin even on PACER).

Verification path (recommended, since this matters for accuracy)

  1. PACER docket for 3:00-cv-04627 — pull the "Attorneys" / party-attorney report and the first complaint; that is the only authoritative source for counsel of record and will show any pro hac vice designations and the N.D. Cal. Civil L.R. local-counsel association.
  2. Stanford NPE Litigation Database case page (https://npe.law.stanford.edu/case/141656) — it hosts the case record and sometimes links related filings; I retrieved only the stub.
  3. The 1999 companion action — BioCentury (Aug. 18, 2000) reports that Incyte had already sued Gene Logic in 1999 on the same two RNA-amplification patents (U.S. 5,716,785 and 5,891,636), while the August 2000 filings concerned Affymetrix, and the '659 database patent was the one asserted against Gene Logic. This suggests possibly two separate N.D. Cal. actions against Gene Logic; if so, the counsel of record may be split across them. Worth pulling both dockets before attributing counsel to "this" case.
  4. Settlement documents — a January 2001 license/settlement would typically name each side's outside counsel in the signature blocks or notice provisions; if a copy is on file with the SEC (Gene Logic S-1/10-K or Incyte 10-Q exhibits), it would resolve the question.

Do not attribute the Foley & Lardner entry to the plaintiff without a PACER confirmation — as written, the only sourced link is an aggregator page that is silent on party alignment.

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

I'll research the defense counsel roster for this case. Let me run several searches.

The first hit ties Peter G. Mack to the case number, but the party he represented isn't stated. Let me dig for the docket and other Gene Logic counsel.

Counsel of record for the defendant (Gene Logic, Inc.)

Bottom line: I could not confirm a counsel roster for the defendant from a primary source in this pass. The N.D. Cal. docket for No. 3:00-cv-04627 (a 2000–2001 case) is not indexed in the free sources reachable here — CourtListener/RECAP returned no docket for the case, and PACER itself was not accessible. What follows is what the record does support, with the gaps flagged rather than filled.

The one lead that ties an attorney to this case number

Name Role Firm / office Note
Peter G. Mack Unknown (party not identified in the source) — likely lead or local patent counsel Foley & Lardner LLP (Washington, DC office) The only attorney listing found that carries this exact case number (3:00-CV-04627, N.D. Cal., "Incyte Genomics Inc v. Gene Logic Inc," 08/17/00) — see the third-party attorney-listing database at https://ai-lab.exparte.com/attorney/6075524/peter-g-mack

Critical caveat on the Mack entry. The listing is a bare name/firm/case-number association. It does not state which side he appeared for, the capacity in which he appeared (lead vs. local), or the filing date of his appearance. Foley & Lardner is a large general-practice IP firm with both plaintiff- and defense-side patent practices, and Peter G. Mack is a long-time Washington, DC patent litigator — so the association is consistent with either the Incyte or the Gene Logic side. Do not treat him as confirmed defense counsel on this record. The earlier section of this summary correctly flagged this reference as unconfirmed, and my searches did not upgrade it.

What I searched and what came back empty

No in-house name confirmed

I found no verifiable name for Gene Logic's general counsel or IP counsel in 2000. Gene Logic's own SEC filings (10-K/proxy) for that period would be the most likely place to find an in-house legal contact or outside-counsel reference, but I could not retrieve and parse them within this pass. Treat the in-house slot as unknown, not "none."

How to confirm (recommended next steps for a human researcher)

  1. PACER (N.D. Cal., 3:00-cv-04627) — pull the docket sheet's "ATTY TO BE NOTICED" entries and the first appearances; the 2000-era CM/ECF docket should list every attorney with firm, address, and party.
  2. Bloomberg Law / Lex Machina / Docket Navigator — all three have counsel fields for this vintage of N.D. Cal. cases and are the fastest authoritative confirmation.
  3. The January 2001 settlement/license documents (the publicly posted contract text at https://www.lawinsider.com/contracts/ksEy56ja0Xa) — signature blocks and "notices" clauses sometimes name outside counsel; worth checking even though the financial terms are redacted.
  4. The companion December 1999 Incyte v. Gene Logic case (same two RNA-amplification patents) — Gene Logic's counsel there is likely the same, and that docket may surface more cleanly.

Consistency note

Nothing found here contradicts the case metadata or the prior sections. The correction already made in the overview — that the '785/'636 exclusive license came from Layton Bioscience, not Stanford — is unaffected by anything in the counsel search. One point to carry forward: because counsel is unverified, any statement in this case file that a particular firm "represented Gene Logic" should be treated as unsourced until the PACER docket is pulled.

Recommendation: mark the defense counsel roster as "requires PACER verification" rather than publishing a name. The single Peter G. Mack lead should be carried as a possible appearance on the case, with an explicit note that the side he represented is unknown.